HPV 16 Is Related to the Progression of Cervical Intraepithelial Neoplasia Grade 2: A Case Series

Table 1

Distribution of HPV types at admission and every three months of followup according to clinical outcome of women with CIN 2.

Clinical outcome	Admission	Follow-up visit (month)				Possibly causal HPV
		3rd	6th	9th	12th
Regression at 3rd	71	71, 58	Na	Neg	16	Undefined
Regression at 6th	16, 58	16	16	16	Na	58
	51	51	Neg	Neg	Neg	51
	26	Na	Neg	Na	16	26
	39, 52, 54, 56, 68	39, 52, 68	52, 51	58	Na	39
	16	16	16	16	16	Undefined
	31	31	31	31	Neg	Undefined
	Neg	Neg	Neg	Neg	16	Undefined
	16, 56, 66	56, 33	Na	33	Na	56
	Neg	16	58	Neg	Na	Undefined
	31	Na	61	Na	Na	Undefined
Regression at 9th	33	33, 16, 58	33	Neg	Neg	33
	16, 67	Na	67	Neg	16	67
	16	16, 39	Neg	Neg	Neg	16
	6, 16, 33	33	Neg	Neg	Neg	33
	39, 51, 53, 56	Na	39, 51	53, 18	39, 59	51
Regression at 12th	Neg	Na	Neg	Na	16, 58, 59	Undefined
	16	16	Na	Na	16	Undefined
Persistence as CIN 1	16	16	Na	16, 61, 81	16, 61, 81	16
	Neg	Neg	53	53	53, 16, 42	Undefined
	16	16	16	Neg	Na	Undefined
	81	51	81	16	Na	Undefined
Persistence as CIN 2	33	Na	Na	Na	33	33
	16, 58	16, 58	16, 58	16, 58	16, 58	16 or 58
	16, 58	16, 58	16, 58	16, 58	Na	16 or 58
	35, 58, 73	Neg	35, 58, 62	35, 58, 16	Na	35 or 58
Progression at 6th	16	16	16	16	Na	16
	16	16	16	16, 66	16, 66	16
	16, 33, 68	16, 33, 68	16, 33	16, 33	16, 33, 68	16 or 33
Progression at 9th	16, 68, 84	16, 84, 42, 58	16, 68, 58	16, 68, 58	16, 18	16
Progression at 12th	39	39	39	39	39	39
	16, 51, 52, 53	16, 52, 45, 84	16, 52, 84	16, 52, 58	16, 52	16 or 52
	16, 52	Na	Na	16, 52	16, 52	16 or 52
	52, 82	52, 82	52	Na	52	52
	6	6, 39	39	Na	Na	Undefined
	31	31	31	Na	Na	31
	16, 56	16, 56, 73	16, 56, 73	Na	Na	16 or 56

New HPV types detected during followup are underlined.